GlassScriptPhysician profile
Sidney Glasofer
NPI 1699932343
$5,882.49
in general payments reported to CMS, 2019-2025
40 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,150 · 2020: $330 · 2021: $490 · 2022: $635 · 2023: $993 · 2024: $1,036 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,263 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,263.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $632.87 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $521.15 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $501.65 | 2019-2025 | |
| Pfizer INC. | $501.04 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $412.09 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $383.31 | 2021-2025 | Verquvo |
| Edwards Lifesciences Corporation | $337.06 | 2020-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.42 | 2019-2025 | Jardiance |
| Abbott Laboratories | $247.15 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $214.48 | 2021-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $196.95 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $166.69 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $154.08 | 2019-2022 | |
| Baxter Healthcare | $132.87 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $129.55 | 2019-2025 | Camzyos, Eliquis |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $82.75 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.06 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.32 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $74.77 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $72.98 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $72.93 | 2019 | |
| Azurity Pharmaceuticals, INC. | $69.87 | 2023-2024 | Edarbyclor, Edarbi, Edarbi |
| Kiniksa Pharmaceuticals, LTD. | $69.54 | 2022-2023 | Arcalyst |
| Bridgebio Pharma, INC. | $58.40 | 2025 | Attruby |
| Cvrx, INC. | $54.16 | 2024 | Barostim Neo System |
| Lundbeck LLC | $43.20 | 2019-2020 | |
| Althera Pharmaceuticals LLC | $36.94 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $33.56 | 2024 | |
| Bardy Diagnostics, INC. | $31.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.88 | 2019-2021 | |
| Boston Scientific Corporation | $30.62 | 2019 | |
| Heartflow, INC. | $24.87 | 2023 | Ffrct |
| Lilly USA, LLC | $21.37 | 2025 | Mounjaro, Zepbound |
| Genzyme Corporation | $20.89 | 2024 | |
| Atricure, INC. | $20.75 | 2025 | Atriclip Laa Exclusion System |
| Cleerly, INC. | $19.52 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Kiniksa Pharmaceuticals International, Plc | $16.27 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $13.87 | 2019 | |
| Medicure Pharma INC. | $13.74 | 2024 | Zypitamag |
| Astellas Pharma US INC | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Glasofer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.